Literature DB >> 9000609

Non-progression of cervical intraepithelial neoplasia estimated from population-screening data.

A B Bos1, M van Ballegooijen, G J van Oortmarssen, M E van Marle, J D Habbema, E Lynge.   

Abstract

Non-progression and duration of preclinical neoplastic lesions of the cervix uteri were studied using screening data from a previously unscreened population, Maribo County, Denmark (1966-82). To estimate regression rates, the incidence of clinical cancer before the screening programme was related to the prevalence and incidence of preclinical lesions estimated from the detection rates of first smear and third and subsequent smears respectively. Duration was estimated from the time lag between the cumulative incidence of preclinical lesions and the combined cumulative incidence of clinical cancer and the estimated 'incidence of regression'. Of all preclinical lesions in women aged 25-50, 24% progressed, 39% regressed and 38% remained. Even if we assume no onset of preclinical lesions above age 50, we estimated that 48% of the preclinical lesions would not progress to clinical cancer in the women's lifetime. The estimated mean duration of preclinical lesions was 16 years. In Maribo County during the 1970s, the positive rate (1.6%) was low compared with current rates in several countries. We conclude that the detection of non-progressive lesions was outweighed by the prevention of clinical cancer.

Entities:  

Mesh:

Year:  1997        PMID: 9000609      PMCID: PMC2222698          DOI: 10.1038/bjc.1997.20

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

Review 1.  Cervical cancer screening: state of the art.

Authors:  A Singer
Journal:  Baillieres Clin Obstet Gynaecol       Date:  1995-03

Review 2.  Natural history of cervical intraepithelial neoplasia: a critical review.

Authors:  A G Ostör
Journal:  Int J Gynecol Pathol       Date:  1993-04       Impact factor: 2.762

3.  Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop.

Authors:  R J Kurman; D E Henson; A L Herbst; K L Noller; M H Schiffman
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

4.  A cohort study of cervical cancer screening in British Columbia.

Authors:  D A Boyes; B Morrison; E G Knox; G J Draper; A B Miller
Journal:  Clin Invest Med       Date:  1982       Impact factor: 0.825

5.  Incidence of cervical cancer following negative smear. A cohort study from Maribo County, Denmark.

Authors:  E Lynge; P Poll
Journal:  Am J Epidemiol       Date:  1986-09       Impact factor: 4.897

6.  Mass screening for cervical cancer in Ostfold county of Norway 1959-77.

Authors:  K Magnus; F Langmark; A Andersen
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

7.  Detection rates for abnormal cervical smears: what are we screening for?

Authors:  A E Raffle; B Alden; E F Mackenzie
Journal:  Lancet       Date:  1995-06-10       Impact factor: 79.321

8.  Duration of preclinical cervical cancer and reduction in incidence of invasive cancer following negative pap smears.

Authors:  G J van Oortmarssen; J D Habbema
Journal:  Int J Epidemiol       Date:  1995-04       Impact factor: 7.196

9.  Natural history of cervical neoplasia: consistent results obtained by an identification technique.

Authors:  L Gustafsson; H O Adami
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

10.  Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer.

Authors:  G J van Oortmarssen; J D Habbema
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

  10 in total
  6 in total

1.  The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996.

Authors:  S Bulk; F J Van Kemenade; L Rozendaal; C J L M Meijer
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

2.  Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented.

Authors:  A E Raffle; B Alden; M Quinn; P J Babb; M T Brett
Journal:  BMJ       Date:  2003-04-26

3.  Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis.

Authors:  Emily A Burger; Inge M C M de Kok; Emily Groene; James Killen; Karen Canfell; Shalini Kulasingam; Karen M Kuntz; Suzette Matthijsse; Catherine Regan; Kate T Simms; Megan A Smith; Stephen Sy; Fernando Alarid-Escudero; Vivek Vaidyanathan; Marjolein van Ballegooijen; Jane J Kim
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

Review 4.  Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review.

Authors:  Matejka Rebolj; Jesper Bonde; Sisse Helle Njor; Elsebeth Lynge
Journal:  BMJ       Date:  2011-05-23

5.  Identification of molecular markers for the early detection of human squamous cell carcinoma of the uterine cervix.

Authors:  Q Cheng; W M Lau; S H Chew; T H Ho; S K Tay; K M Hui
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

6.  Multiple sexual partners and vaginal microecological disorder are associated with HPV infection and cervical carcinoma development.

Authors:  Yu Huang; Xinzhi Wu; Ying Lin; Wenzhou Li; Jiahua Liu; Baozhi Song
Journal:  Oncol Lett       Date:  2020-06-16       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.